{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T08:36:53Z","timestamp":1792831013030,"version":"4.5.0"},"reference-count":27,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:00:00Z","timestamp":1792800000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:00:00Z","timestamp":1792800000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pac J Clncl Oncology"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>Ongoing disruptions to opioid supply in Australia have raised ongoing concerns about their impact on cancer pain management. The withdrawal of hydromorphone slow\u2010release (SR) tablets from the Australian market has presented challenges to advanced cancer pain management. This study aimed to determine how this affected the utilisation of alternative slow\u2010release opioids in patients with advanced cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort study was conducted at a quaternary cancer centre, comparing opioid prescribing patterns across two 12\u2010month periods: before hydromorphone SR tablet discontinuation was announced and after its discontinuation. Inpatient and outpatient prescribing data were analysed for adult patients with incurable advanced or metastatic cancer who first presented to the centre during each study period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 2856 patients were included (\n                      <jats:italic>n<\/jats:italic>\n                      = 1475 pre and\n                      <jats:italic>n<\/jats:italic>\n                      = 1381 post hydromorphone SR discontinuation). Following hydromorphone SR withdrawal, opioid prescribing patterns shifted. Methadone use rose modestly (adjusted odds ratio [aOR]\u00a01.42,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.07), accompanied by a doubling of median dose (45\u00a0mg vs. 22.5\u00a0mg;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.005). Morphine use declined (aOR\u00a00.69,\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001), yet daily OMEDD increased by \u223c20% (95% confidence interval 1.01\u20131.37). Tapentadol (aOR\u00a01.40,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.01) and buprenorphine (aOR\u00a01.37,\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001) were prescribed more frequently, without corresponding dose escalation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Following hydromorphone SR withdrawal, the frequency of methadone use increased and median doses doubled. Research incorporating national datasets is needed to clarify the broader impact of opioid supply interruptions. These findings indicate a potential need to reframe the place of methadone in practice, and potentially upscale the focus of clinician training on its safe and effective use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ajco.70216","type":"journal-article","created":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T07:44:51Z","timestamp":1792827891000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Opioid Prescribing Changes in Advanced Cancer Before and After Withdrawal of Hydromorphone Slow\u2010Release Tablets"],"prefix":"10.1111","author":[{"given":"Aaron K.","family":"Wong","sequence":"first","affiliation":[{"name":"Sir Peter MacCallum Department of Oncology The University of Melbourne  Melbourne Australia"},{"name":"Peter MacCallum Cancer Centre  Melbourne Australia"},{"name":"The Royal Melbourne Hospital  Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"McManus","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre  Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Vogrin","sequence":"additional","affiliation":[{"name":"Department of Medicine St Vincent's Hospital Melbourne University of Melbourne  Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youseph","family":"Dib","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre  Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monnette","family":"Samo","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre  Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"La","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre  Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Le","sequence":"additional","affiliation":[{"name":"Sir Peter MacCallum Department of Oncology The University of Melbourne  Melbourne Australia"},{"name":"Peter MacCallum Cancer Centre  Melbourne Australia"},{"name":"The Royal Melbourne Hospital  Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Philip","sequence":"additional","affiliation":[{"name":"Sir Peter MacCallum Department of Oncology The University of Melbourne  Melbourne Australia"},{"name":"The Royal Melbourne Hospital  Melbourne Australia"},{"name":"Department of Medicine University of Melbourne Eastern Hill Campus  Melbourne Australia"},{"name":"St Vincent's Hospital Palliative Care Service  Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,24]]},"reference":[{"issue":"3","key":"e_1_2_10_2_1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.critrevonc.2011.06.002","article-title":"End\u2010of\u2010life Care Across Southern Europe: A Critical Review of Cultural Similarities and Differences Between Italy, Spain and Portugal","volume":"82","author":"Me\u00f1aca A.","year":"2012","journal-title":"Critical Reviews in Oncology\/Hematology"},{"key":"e_1_2_10_3_1","unstructured":"Therapeutic Goods Administration \u201cInformation About Supply of Oral Opioid Products \u201d (2026)."},{"key":"e_1_2_10_4_1","doi-asserted-by":"crossref","DOI":"10.18356\/9789210014892","volume-title":"Report of the International Narcotics Control Board for 2022","author":"International Narcotics Control Board","year":"2023"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15143676"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/spcare\u20102024\u2010005028"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2015.12.011"},{"key":"e_1_2_10_8_1","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/482081","article-title":"Morphine versus Hydromorphone: Does Choice of Opioid Influence Outcomes?","volume":"2015","author":"Gulur P.","year":"2015","journal-title":"Pain Research and Treatment"},{"key":"e_1_2_10_9_1","unstructured":"Australian and New Zealand College of Anaesthetists.Opioid Dose Equivalence Calculation Table(2021) https:\/\/fpm.anzca.edu.au\/documents\/opioid\u2010dose\u2010equivalence.pdf."},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2005.01.007"},{"key":"e_1_2_10_11_1","unstructured":"Palliative Care Australia.Mediarelease\/Ongoing\u2010Pain\u2010Medicine\u2010Shortages\u2010Risk\u2010Quality\u2010Of\u2010Life\u2010For\u2010All\u2010Australians(2026)."},{"key":"e_1_2_10_12_1","volume-title":"WHO Guidelines for the Pharmacological and Radiotherapeutic Management of Cancer Pain in Adults and Adolescents","author":"World Health Organisation","year":"2018"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2023.06.022"},{"issue":"11","key":"e_1_2_10_14_1","article-title":"Tapentadol: A Comprehensive Review of Its Role in Pain Management","volume":"16","author":"Zavaleta\u2010Monestel E.","year":"2024","journal-title":"Cureus"},{"issue":"2","key":"e_1_2_10_15_1","article-title":"Methadone for Cancer Pain","volume":"2","author":"Nicholson A. B.","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol31120561"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2018.12.001"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520\u2010025\u201009286\u2010z"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2019.0243"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02198"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269216311406577"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(12)70040\u20102"},{"issue":"9","key":"e_1_2_10_23_1","first-page":"135","article-title":"Opioid Rotation in Cancer Pain Treatment","volume":"115","author":"Schuster M.","year":"2018","journal-title":"Deutsches \u00c4rzteblatt International"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2006.01.010"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2023.0541"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0885\u20103924(02)00390\u20101"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/147323000803600218"},{"issue":"8","key":"e_1_2_10_28_1","article-title":"Hydromorphone for Cancer Pain","volume":"8","author":"Li Y.","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.70216","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajco.70216","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.70216","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T07:44:53Z","timestamp":1792827893000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajco.70216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,24]]},"references-count":27,"alternative-id":["10.1111\/ajco.70216"],"URL":"https:\/\/doi.org\/10.1111\/ajco.70216","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"value":"1743-7555","type":"print"},{"value":"1743-7563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,24]]},"assertion":[{"value":"2026-05-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70216"}}